You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The WHO said that before point-of-care immunodiagnostic tests can be recommended, they must be validated in the appropriate populations and settings.
The collaboration includes setting up a new testing laboratory that will investigate the use of alternative chemical reagents for test kits.
FIND and WHO are collaborating again, this time to to perform a standardized evaluation of currently available immunoassays.
Some believe that more could be done to help deliver diagnostics to the European market.
The two organizations are collaborating to perform a standardized evaluation of currently available molecular diagnostic tests to assess test performance.
Initially, FIND and the WHO will work to develop national essential diagnostics lists, as well as to collect data to support countries in their aim to provide universal health coverage.
Mere weeks after the 2019-nCoV sequence was released, firms, agencies, and research groups have already created PCR-based tests.
At Medica, the two firms, whose tests have received WHO prequalification, said their tests were seeing high adoption rates in lower-resource nations.
The firm's CEO said that the approval enables global funders and national ministries of health to expand access to HIV self-testing, allowing diagnosis and treatment.
Having recently won prequalification status from the World Health Organization the British Columbia-based firm is also considering US regulatory options.